ESTRADURIN Drug Patent Profile
✉ Email this page to a colleague
When do Estradurin patents expire, and when can generic versions of Estradurin launch?
Estradurin is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in ESTRADURIN is polyestradiol phosphate. There is one drug master file entry for this compound. Additional details are available on the polyestradiol phosphate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ESTRADURIN?
- What are the global sales for ESTRADURIN?
- What is Average Wholesale Price for ESTRADURIN?
Summary for ESTRADURIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| DailyMed Link: | ESTRADURIN at DailyMed |
US Patents and Regulatory Information for ESTRADURIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | ESTRADURIN | polyestradiol phosphate | INJECTABLE;INJECTION | 010753-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
